Elsevier

The Lancet

Volume 359, Issue 9312, 30 March 2002, Pages 1121-1122
The Lancet

Research Letters
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

https://doi.org/10.1016/S0140-6736(02)08158-8Get rights and content

Summary

Hypersensitivity to abacavir affects about 4% of patients who receive the drug for HIV-1 infection. We did a retrospective, case-control study to identify multiple markers in the vicinity of HLA-B associated with hypersensitivity reactions. HLA-B57 was present in 39 (46%) of 84 patients versus four (4%) of 113 controls (p< 0·0001). However, because of low numbers of women and other ethnic groups enrolled, these findings relate largely to white men. The lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study compared with a previous report highlights that predictive values for markers will vary across populations. Clinical monitoring and management of hypersensitivity reactions among patients receiving abacavir must remain unchanged.

References (5)

There are more references available in the full text version of this article.

Cited by (743)

  • Skin testing as a biomarker in drug allergy

    2023, Annals of Allergy, Asthma and Immunology
  • Pharmacogenomics of Drug Hypersensitivity: Technology and Translation

    2022, Immunology and Allergy Clinics of North America
View all citing articles on Scopus
View full text